cbdMD (AMEX:YCBD) Stock, Quote.Headers.trade-ideas

cbdMD

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

Movimiento de acciones

Pre-Market Outlook

Markets

Trading Ideas

ALTI

ARGX

ASNS

BOOM

BWMX

CERT

CMRE

INNV

MAZE

MSPR

NEXA

ONVO

RXRX

SLSR

STSS

VERO

YCBD

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

News

Movers

AKAN

CETX

ISRG

JDZG

JTAI

MGPI

MTEM

NFLX

NKGN

NTBL

NUZE

OLMA

ORGS

PEGY

SOBR

STAF

TNON

VSME

VTAK

Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

cananbis debt (geralt and Kindel Media by Pixabay)(80)

Cannabis

Earnings

cbdMD, Inc. (NYSE: YCBD), an operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs announced on Wednesday its financial results for the third quarter of fiscal 2024 ending June 30, 2024. Year-over-year, operational losses improved markedly, shrinking from $1.8 million in the third quarter of fiscal 2023 to $0.38 million in the third quarter of fiscal 2024, the company highlighted in the press release. Ronan Kennedy, the company&#39;s CEO and CFO, praised the financial results.

cbdMD Reduces Operating Loss, Reports Positive Net Income For Q3 And 15% YoY Drop In Net Sales

cbdMD Inc

Press Releases

cbdMD Announces Additional Conversions of Its Convertible Notes

cbdMD Announces It Has Fully Satisfied Its Notes

cbdMD, Inc. to Host Conference Call to Discuss December 31, 2024 First Quarter of Fiscal Year 2025 Results

cbdMD Generates $5.1 Million in Revenue, Positive Earnings

cbdMD Achieves Key Milestone in UK Novel Food Regulatory Approval

Herbal Oasis Announces Distribution Agreement to Launch Statewide in Alabama and Select Florida Panhandle Markets

cbdMD, Inc. Announces Shareholder Approval of Automatic Conversion of Series A Preferred Stock and Other Results from Annual Meeting

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2025, Second Quarter of Fiscal Year 2025 Results

cbdMD Delivers Continued Revenue Growth and Trend Towards Profitability in Second Fiscal Quarter

Herbal Oasis Expands Footprint with New Distribution Agreement in Georgia

YCBDPA

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Athira Pharma

Aytu BioPharma

Biofrontera

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

CNS Pharma

Cocrystal Pharma

China Pharma Holding

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Evoke Pharma

Gelteq

Hoth Therapeutics

Impact BioMedical

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

ProPhase Labs

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

Talphera

Traws Pharma

VYNE Therapeutics

Maxim Group

Comments

cbdMD

cbdMD (AMEX:YCBD) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell